🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to evaluate the effects of pharmacologic FXa i...
Status
Completed
Location
Hennepin County Medical Center
Start Date
2015-07
Trial ID
NCT02339415
Treatments Being Tested
This study will evaluate the establishment of anticoagulation ("re-anticoag...
Status
Completed
Location
Quintiles
Start Date
2014-03
Trial ID
NCT02207257
The objective of this study is to assess the efficacy, safety and dose-resp...
Status
Completed
Location
Multiple Locations
Start Date
2006-07
Trial ID
NCT01203072
PER977 monotherapy and co-administration following 60 mg edoxaban will have...
Status
Completed
Location
Duke Clinical Research, Unit 200
Start Date
2013-07
Trial ID
NCT01826266
Treatments Being Tested
This Phase 1 study consists of 2 parts. Part 1 will be an open-label, rando...
Status
Completed
Location
Quintiles
Start Date
2013-10
Trial ID
NCT02047565
Treatments Being Tested
A randomized, double-blind, placebo-controlled study to evaluate the effica...
Status
Terminated
Location
Qps-Mra, Llc.
Start Date
2021-10-13
Trial ID
NCT04593784
Treatments Being Tested
NOAH is an investigator-initiated, prospective, parallel-group, double-blin...
Status
Terminated
Location
Several Sites
Start Date
2016-02
Trial ID
NCT02618577
Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edo...
Status
Completed
Location
UK Aachen
Start Date
2020-11-12
Trial ID
NCT04542408
A single centre, double-blind, randomized, parallel group, placebo-controll...
Status
Completed
Location
QPS Netherlands B.V.
Start Date
2021-10-29
Trial ID
NCT05152420
Treatments Being Tested
The purpose of this study is to evaluate the ability of PRT064445 to revers...
Status
Completed
Location
Multiple Locations
Start Date
2012-12
Trial ID
NCT03551743
Treatments Being Tested